A Post Authorization Study, Designed to Learn More About the Safety and Efficacy of the Use of VELCADE (Bortezomib) in the Netherlands.
Phase of Trial: Phase IV
Latest Information Update: 13 Jan 2014
At a glance
- Drugs Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms VALEO
- Sponsors Janssen-Cilag
- 05 Apr 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.
- 05 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.